https://pubmed.ncbi.nlm.nih.gov/15269313/
Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with irinotecan-refractory colorectal cancer.
cetuximabmonotherapyplusirinotecanrefractory
https://pubmed.ncbi.nlm.nih.gov/15277259/?utm_source=Firefox&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1jmC0p0kwOiCcoFdWNnDLt9teiWG5XXLdmSwZYr5NJoUy2Csb8&fc=20220328160043&ff=20220328160204&v=2.17.6
The combination of CPT-11/L-OHP is an active regimen as front-line treatment in AGC with a favourable toxicity profile and deserves further evaluation in...
combinationirinotecancptplusoxaliplatin
https://www.gov.uk/drug-device-alerts/company-led-medicines-recall-irinotecan-200mg-slash-260ml-in-sodium-chloride-0-dot-9-percent-w-slash-v-intravenous-infusion-and-infliximab-remsima-intravenous-infusion-in-sodium-chloride-0-dot-9-percent
Qualasept Ltd t/a Bath ASU is recalling a specific batch of Irinotecan 200mg/260mL in sodium chloride 0.9% w/v intravenous infusion and specific batches of...
sodium chloridecompanyledmedicinesrecall
https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2023-0163.html
To find the recommended dose of eribulin that can be given in combination with irinotecan and temozolomide to treat relapsed and/or refractory solid tumors.
phase ibin combinationtrialeribulinirinotecan
https://pubmed.ncbi.nlm.nih.gov/15238986/?utm_source=Firefox&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1jmC0p0kwOiCcoFdWNnDLt9teiWG5XXLdmSwZYr5NJoUy2Csb8&fc=20220328160043&ff=20220328160204&v=2.17.6
To compare irinotecan (CPT-11)+gemcitabine vs CPT-11 alone as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC) progressing...
the second lineirinotecanplusgemcitabinevs